VKTX Company Profile and Key Details

VKTX has shown mixed momentum, gaining 5.54% over the past week and -0.04% over the past quarter, though year-to-date performance is down -4.72%. Short-term trend indicators are mixed aligned (SMA20 8.81%, SMA50 1.77%, SMA200 4.75%). The stock’s 14-day RSI is 55.58 (neutral), while the ATR of 2.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.59% below its high and over 74.26% above its low. Average 10-day trading volume of 2.82 million shares is in line with the 3-month average of 2.68 million, indicating normal recent market interest.

Viking Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.47. This means the shares are trading above this model’s fair value.

Viking Therapeutics, Inc. (NASDAQ:VKTX) closed at $30.00 USD, losing -$1.18 (-3.78%) from the previous close of $31.18. The stock is currently mid-range between its 52-week high and low $22.96 and $43.15. With a market capitalization of about $3.48 billion, Viking Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 2.67 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Viking Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Lian, the company employs approximately 45 people and listed since April 28, 2015. Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Viking Therapeutics, Inc. generated EPS of -$3.18 over the past year. Five-year average earnings growth is -42.46%. Wall Street analysts project EPS growth of -9.28% annually over the next five years. The latest quarter delivered EPS of -$1.37. The next quarter is forecast at -$1.00. Next year's EPS is expected at -$17.22. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 7 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $38.00. The high target offers 300.9% upside. The low target suggests 21.87% downside. The mean target is $98.58. This offers 216.16% upside. Viking Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 29, 2026, missed forecasts by 35.64%. The prior quarter beat by 55.06%. Over the last six quarters, Apple has recorded several small beats. These include 14.29% in February 05, 2025.

Viking Therapeutics, Inc. has 112.44 million shares outstanding. The public float is 219.96 million shares, elevated short interest at 28.46% of float. This equals 26.68 million shares. The short ratio is 3.05 days. Institutional investors hold 64.69% of the float. Insiders own 2.81%. LIGAND PHARMACEUTICALS INC holds 5.82 million shares, Lian Brian has 2.50 million shares and Mancini Marianna has 409.19 thousand shares. Over the past six months, insider transactions show net selling. They sold 25.50 thousand shares across 4 transactions.

Viking Therapeutics, Inc. trades at a P/E ratio of -7.39, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.96 trading at moderately above to book value. The P/FCF stands at -10.29, also above market averages.

Our AI price prediction model suggests that Viking Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.86%, with price expected at $31.76 by May 14, 2026, within a range of $30.26 to $33.25 3-Month Outlook: Projected rise of 48.78%, reaching $46.39 by July 29, 2026, with a range of $44.70 to $47.89. 1-Year Outlook: Projected loss of -12.25%, with price at $27.36 by April 30, 2027, within a range of $20.38 to $36.01.

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares are flat -4.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Viking Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.39. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $66.25, suggesting 112.48% upside. Our AI forecast model points to short-term strength (1.86% over two weeks), a medium-term rise (48.78% over three months), and a longer-term loss (-12.25% over one year), with expected trading ranges indicating moderate volatility.